Meilleurs médecins de leucémie lymphoblastique aiguë à l'étranger — Page 3

Le Dr Ofer Spielberg est un onco-hématologue spécialisé, se concentrant sur les cancers du sang tels que la leucémie.

• Exerce au centre médical Assuta
• Expertise en onco-hématologie, le domaine dédié aux cancers du sang
• Fournit un traitement ciblé pour la leucémie lymphoblastique aiguë

Le Dr Avichai Shimoni est directeur de la transplantation de moelle osseuse au Sheba Medical Center. Il traite des cancers du sang complexes. Il a effectué un fellowship spécialisé au MD Anderson Cancer Center. Le Dr Shimoni utilise des greffes allogéniques et autologues pour les patients à haut risque. Il est professeur et président d'hématologie à l'Université de Tel Aviv.

• Nommé parmi les meilleurs médecins d'Israël par Forbes pour 2025 et 2026.
• Auteur de plus de 250 articles scientifiques sur les thérapies cellulaires et la transplantation.
• Propose une thérapie par cellules CAR-T pour la leucémie, le lymphome et le myélome multiple.
• Travaille au Sheba Medical Center, l'un des 10 meilleurs hôpitaux au monde selon Newsweek.

Le Dr Abraham Avigdor est directeur de l'Institut d'hématologie du centre médical Sheba. Il est une autorité mondiale en matière de lymphome, de thérapie CAR-T et de cancers du sang complexes. Le Dr Avigdor a fondé le groupe de travail israélien sur les lymphomes. Il participe à la direction d'une clinique classée 7e au niveau mondial par Newsweek en 2026.

• Auteur de plus de 130 publications scientifiques sur l'hémato-oncologie et la thérapie cellulaire.
• Pionnier de l'intégration de la thérapie par cellules CAR-T pour le lymphome et le myélome.
• Dirige des programmes de greffe de moelle osseuse allogénique et autologue.
• A été président du groupe d'étude israélien sur les lymphomes.

Le Dr Hila Magen est une hématologue-oncologue israélienne de premier plan au centre médical Sheba. Elle dirige l'unité de myélome multiple et d'amylose. Le Dr Magen est spécialisée dans le traitement des troubles complexes des plasmocytes et du myélome à haut risque. Elle est chercheuse principale pour des programmes innovants de thérapie CAR-T au point de service. Ses travaux intègrent des immunothérapies avancées dans les soins cliniques de routine.

• Auteure de plus de 100 publications scientifiques et d'études marquantes sur le myélome.
• A effectué des fellowships au MD Anderson et à l'Université des sciences médicales de l'Arkansas.
• Réalise des thérapies par cellules CAR-T et des greffes de moelle osseuse.
• Travaille au centre médical Sheba, classé 7e mondial en 2026 par Newsweek.

Reconnu par Forbes comme l'un des meilleurs médecins en 2018, le Dr Stepensky a réalisé plus de 3 500 greffes de moelle osseuse au Hadassah Medical Center.

• 28 années de spécialisation dans les greffes de moelle osseuse pédiatriques
• Axé sur les cancers du sang rares chez les enfants
• Connu parmi les patients comme « celui qui transplante la vie »
• Dirige une unité dédiée à l'hématologie pédiatrique

Le Dr Iris Kventsel est hémato-oncologue pédiatrique et spécialiste des greffes de moelle osseuse au centre médical Sheba. Elle traite les sarcomes infantiles tels que le sarcome d'Ewing et l'ostéosarcome à l'hôpital pour enfants Edmond et Lily Safra. Le Dr Kventsel intègre des thérapies ciblées et des traitements cellulaires pour les cancers pédiatriques complexes. Elle fait partie du corps enseignant de la faculté de médecine de l'université de Tel Aviv.

• Spécialisée dans la greffe de moelle osseuse et la thérapie par cellules CAR-T pour les patients pédiatriques.
• Recherche sur la prédisposition génétique au cancer, notamment le syndrome de Li-Fraumeni et les gènes de susceptibilité.
• Publie dans des revues majeures sur la biologie des cellules souches et l'oncologie chirurgicale (HIPEC).
• Travaille au centre médical Sheba, classé parmi les 10 meilleurs hôpitaux du monde.

Le Dr Elad Jacoby est un pionnier de la thérapie par cellules CAR-T pédiatriques en Israël. Il dirige le Centre de thérapie cellulaire pédiatrique au Sheba Medical Center. Le Dr Jacoby est spécialisé dans le traitement des leucémies et lymphomes pédiatriques récidivants et à haut risque. Il a effectué des stages à Johns Hopkins et au National Cancer Institute des États-Unis.

• Directeur médical du Centre de biothérapie avancée au Sheba Medical Center.
• Auteur de plus de 240 publications scientifiques en hémato-oncologie pédiatrique.
• Certifié en pédiatrie ainsi qu'en hématologie et oncologie pédiatrique.
• Dirige l'intégration de la thérapie par cellules CAR-T avec la greffe de moelle osseuse.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Leader mondialement reconnu dans le domaine de la leucémie lymphoïde chronique (LLC) et des lymphomes – le Dr Bosch est un pionnier des nouveaux traitements et de la recherche moléculaire à l'Hôpital Quiron de Barcelone.

• Dirige plus de 80 essais cliniques, de la phase 1 à la phase 3
• A publié plus de 100 études dans des revues prestigieuses telles que NEJM et Nature Medicine
• Dirige le groupe espagnol de recherche sur la LLC et les essais cliniques
• Post-doctorat à l'Institut de génétique du cancer de l'Université Columbia

Chef du service d'hématologie au centre médical Hadassah – Le professeur Ben-yehuda a été pionnière dans la thérapie génique et les greffes de moelle osseuse pour la leucémie lymphoblastique aiguë.

• Formée au Memorial Sloan-Kettering Cancer Center à New York
• Première femme doyenne de la faculté de médecine Hadassah
• Spécialisée dans le diagnostic moléculaire et l'immunologie
• Lauréate du prix « Healing with the Heart » pour ses soins exceptionnels aux patients

La professeure Zila Zuckerman est spécialisée en hématologie et en transplantologie au Rambam Medical Center.

• Experte dans le traitement de la leucémie lymphoblastique aiguë
• Spécialisée en transplantologie pour les troubles sanguins
• Professeure avec une vaste expérience académique et clinique

La Prof. Elke Jaeger est l'une des meilleures oncologues d'Allemagne selon le classement Focus ; elle dirige le service d'oncologie et d'hématologie de la clinique Nordwest.

• Spécialisée dans le traitement des sarcomes
• 41 années d'expérience en oncologie
• Chef du service d'oncologie et d'hématologie

Chef du service d'hématologie à la clinique Nordwest avec 36 années d'expérience – Le Dr Weidmann est spécialisé dans le traitement des troubles sanguins.

• Se concentre sur les cas de lymphome non hodgkinien
• Professeur avec une vaste expérience académique et clinique
• Dirige un secteur d'hématologie dédié

Professeur associé en hématologie avec plus de 50 publications – Le Dr Eren est spécialisé dans les troubles sanguins à l'hôpital universitaire Biruni.

• A terminé sa formation de sous-spécialité en hématologie à l'hôpital de formation et de recherche d'Istanbul
• Membre de la Société européenne d'hématologie et de l'Association turque d'hématologie
• Lauréat du prix du jeune chercheur au Congrès national d'hématologie
• Maîtrise l'anglais pour les consultations internationales de patients

Le Dr Apak est spécialisé en hématologie-oncologie pédiatrique avec plus de _doctor_6792_ années d'expérience, se concentrant sur la leucémie lymphoblastique aiguë à l'hôpital universitaire Biruni.

• Expert en transplantation de moelle osseuse et thérapie par cellules CAR-T
• Auteur de 75 publications internationales en oncologie pédiatrique
• Chef de la division d'hématologie-oncologie pédiatrique à l'Université d'Istanbul-Cerrahpaşa
• Membre de la Société turque de pédiatrie et de l'Association turque de médecine de l'adolescent

Le professeur Fabio Ciceri dirige des essais pionniers de thérapie cellulaire et génique pour la leucémie lymphoblastique aiguë à l'hôpital San Raffaele.

• Chef de l'unité d'hématologie et de transplantation de moelle osseuse
• Investigateur principal dans des essais cliniques sur les cancers hématologiques
• Auteur de plus de 180 publications scientifiques
• Membre du Groupe européen de transplantation de sang et de moelle osseuse

Chef de l'un des plus grands départements de greffe de moelle osseuse d'Italie – le Dr Peccatori supervise plus de 90 greffes allogéniques par an à San Raffaele.

• 29 années d'expérience en hématologie et en greffe de moelle osseuse
• Auteur de plus de 70 études sur la leucémie, le myélome et la transplantation
• Spécialisé dans les greffes allogéniques pour les leucémies aiguës
• Membre de sociétés européennes et italiennes de transplantation
• A réalisé plus de 900 traitements, y compris des cas complexes

Spécialiste de la leucémie aiguë et de la greffe de cellules souches, le professeur Omay apporte 36 années d'expertise en hématologie acquise au sein des meilleures institutions turques.

• Chef du service d'hématologie à l'hôpital Emsey
• Formé en hématologie moléculaire à l'école de médecine de Mie, au Japon
• Auteur de plus de 65 articles scientifiques sur les traitements hématologiques
• Réalise des greffes de cellules souches autologues et allogéniques